View All Officers

Takanori Yokota, M.D., Ph.D.


Dr. Yokota graduated from Tokyo Medical and Dental University in 1984 and completed his Residency and Fellowship in Musashino Red Cross Hospital in 1986. He studied molecular biology and gene therapy in Bredesen’s lab in Burham Institute (CA, USA) and Buck Center for Aging Research (CA, USA) in 1998-2000. He accepted a position as Professor in 2010, and Chairman of Department Neurology and Neurological Science, Tokyo Medical and Dental University. Dr. Yokota published more than 200 outstanding scientific papers in basic and clinical neurology and molecular medicine. Dr. Yokota’s research has focused on gene therapy with oligonucleotide drug and the molecular mechanism of Neurodegenerative diseases. His group has developed DNA/RNA oligonucleotide (HDO) as a third class of oligonucleotide drug which is highly potent and can regulate extra-hepatic organs including brain by crossing blood-brain-barrier (BBB) and started “RENA Therapeutics”.

He also developed the technology for crossing of high molecular drugs through BBB using glucose transporter 1 recycling and funded “BRAIZON Therapeutics”.

In OTS, he has been a BOD member since 2017 and been playing a role in expanding oligonucleotide research in Asia. He has been the president of Nucleic Acid Therapeutics Society of Japan (NATS-J) as Japanese OTS since 2018.

Dr. Yokota is a leading scientist as well as neurologist for next generation of gene therapy with oligonucleotide drugs.

  • President of Nucleic Acid Therapeutics Society of Japan (NATS-J)
  • Boards of Japanese Society of Neurology
  • Boards of Japanese Society of Neuroimmunology
View All Officers